|
Sign In to gain access to subscriptions and/or personal tools.
|
 |
Evidence-based guidelines for management of attention-deficit/hyperactivity
disorder in adolescents in transition to adult services and in adults: recommendations
from the British Association for Psychopharmacology
David J. Nutt1*,
Kevin Fone2,
P. Asherson3,
D Bramble4,
P Hill5,
K Matthews6,
K A Morris7,
P Santosh8,
Edmund Sonuga-Barke9,
E Taylor8,
M Weiss10,
S Young11
1 Psychopharmacology Unit, University of Bristol, Bristol, UK.
2 University of Nottingham, Nottingham UK.
3 MRC Social Genetic Developmental Psychiatry, Institute of Psychiatry,
King's College London, UK.
4 Telford and Wrekin PCT, Shrewsbury, UK.
5 London, UK.
6 University of Dundee, Dundee UK.
7 c/o Psychopharmacology Unit, University of Bristol, Bristol, UK.
8 Institute of Psychiatry, London, UK.
9 University of Southampton, Southampton, UK.
10 University of British Columbia, Vancouver, Canada.
11 Bethlem Royal Hospital, Kent, UK.
* To whom correspondence should be addressed.
 |
Abstract |
|---|
Attention-deficit/hyperactivity disorder (ADHD) is an established diagnosis in
children, associated with a large body of evidence on the benefits of treatment.
Adolescents with ADHD are now leaving children's services often with no readily
identifiable adult service to support them, which presents problems as local
pharmacy regulations often preclude the prescription of stimulant drugs by general
practitioners (GPs). In addition, adults with ADHD symptoms are now starting to
present to primary care and psychiatry services requesting assessment and treatment.
For these reasons, the British Association for Psychopharmacology (BAP) thought it
timely to hold a consensus conference to review the body of evidence on childhood
ADHD and the growing literature on ADHD in older age groups. Much of this initial
guidance on managing ADHD in adolescents in transition and in adults is based on
expert opinion derived from childhood evidence. We hope that, by the time these
guidelines are updated, much evidence will be available to address the many
directions for future research that are detailed here.
Key Words:
ADHD, hyperkinetic disorders, hyperactivity, impulsivity, psychostimulants, psychotherapy, co-morbidities
First published on November 8, 2006, doi:10.1177/0269881106073219
Journal of Psychopharmacology 2007;21:10.
A more recent version of this article appeared on January 1, 2007
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M Koesters, T Becker, R Kilian, J. Fegert, and S Weinmann
Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder
J Psychopharmacol,
September 1, 2009;
23(7):
733 - 744.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J Godfrey
Safety of therapeutic methylphenidate in adults: a systematic review of the evidence
J Psychopharmacol,
March 1, 2009;
23(2):
194 - 205.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. A. Ahmed, S. Cress, and L. Lovett
Adult ADHD: the new kid on the block has grown up
Psychiatr. Bull.,
January 1, 2009;
33(1):
37 - 37.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Akram, A H Thomson, A C Boyter, and M J S Morton
Characterisation and evaluation of UK websites on attention deficit hyperactivity disorder
Arch. Dis. Child.,
August 1, 2008;
93(8):
695 - 700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weiss, S. A. Safren, M. V. Solanto, L. Hechtman, A. L. Rostain, J. R. Ramsay, and C. Murray
Research Forum on Psychological Treatment of Adults With ADHD
J Atten Disord,
May 1, 2008;
11(6):
642 - 651.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Verster and D. Cox
ADHD, methylphenidate and driving: does some legislation endanger public health?
J Psychopharmacol,
May 1, 2008;
22(3):
227 - 229.
[PDF]
|
|
|
|
|
